- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04220593
Effects of Transcranial Direct Current Stimulation Associated With Cognitive Training in Alzheimer's Disease
6. ledna 2020 aktualizováno: Suellen Marinho Andrade, Federal University of Paraíba
Effects of Transcranial Direct Current Stimulation Associated With Cognitive Training in Alzheimer's Disease: Clinical Trials, Triple-blind and Randomized
Alzheimer's disease (AD) is characterized by a progressive decline in cognitive functions, interfering with autonomy and independence.
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM 5), mnemonic dysfunction in AD must be related to aphasia, apraxia, agnosia, or changes in executive function.
The clinical picture of the disease can be described as mild, moderate and severe.
In the mild phase, the patient is disoriented and with difficulties in thinking, in later stages memory lapses become more intense and frequent.
The symptoms of apraxia, aphasia and agnosia appear, causing a noticeable impact on the performance of simple daily activities, and neuropsychiatric and behavioral symptoms are expressed.
Existing pharmacological treatments for AD treatment are able to minimize the symptoms of the disease, but are not able to promote cure.
Therefore, studies have sought to better understand non-pharmacological strategies, aiming at optimizing the benefits of using the drug.
Studies have suggested that tDCS promotes significant effects on cognitive processes assessed through cognitive tasks, not only in healthy individuals but also in clinical populations.
Cognitive training (TCog) has similarly shown excellent results in the treatment of cognitive deficits due to AD.
Thus, the present study aims to investigate when (before, during or after) the tDCS should be applied to potentiate the effects of TCog in people with AD by comparing four protocols of application of neurostimulation associated with TCog.
Přehled studie
Detailní popis
It consists of a randomized, triple-blind, placebo-controlled clinical trial.
The AETCC must be associated with the Tcog.
Patients diagnosed in mild to moderate AD will be randomized into four groups: G1, aETCC before TCog; G2, aETCC during TCog; G3 aETCC after TCog and G4: simulated aETCC during TCog.
Groups G1, G2 and G3 will receive the active current, while G4 will receive the simulated current.
In each condition, an initial baseline assessment (T0) will be performed after 12 sessions (T1) and three weeks after the end of interventions (T2).
The outcomes evaluated will be: cognition, executive function, functionality, neuropsychiatric symptoms and occupational performance.
For all analyzes, SPSS (Statistical Package for Social Sciences - SPSS Inc, Chicago IL, USA) for Windows, Version 20.0, will be used and considered as significant, an alpha value of 5% (p <0.05 ).
Typ studie
Intervenční
Zápis (Očekávaný)
80
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
PB
-
João Pessoa, PB, Brazílie
- Nábor
- Suellen Andrade
-
Kontakt:
- Gabriella Conserva
- Telefonní číslo: +55 83 98747-1386
- E-mail: gabriellac.to@gmail.com
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
55 let až 85 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
Patients will be included in this study following the following requirements: (a) age between 55 and 85 years; (b) probable diagnosis AD; (c) scores higher than 18 on the Mini Mental State Examination (MMSE); (e) did not receive regular cognitive intervention within 3 months prior to the start of this clinical trial.
Exclusion Criteria:
- Patients will be excluded from this study while not meeting the following criteria: (a) individuals with severe metabolic and / or cardiac disorders, alcoholism, focal neurological disorders and associated psychiatric disorders; (b) use of hypnotics and benzodiazepines two weeks prior to study initiation; or (c) use of medication with cholinergic inhibitors and memantine for more than two months prior to this clinical trial; (d) or with any condition that could impair the neuropsychological assessment process or receive a cognitive intervention protocol from the study will be excluded from the study. In addition, participants with transient or definitive pacemakers, cochlear implants, or intracranial aneurysm clips will be excluded; (e) individuals with a history of seizures; (f) the presence of tumors, epilepsy or substance abuse.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: aETCC before TCog
Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog).
Duration: 20 minutes; Intensity: 2mA.
|
2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions.
In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
|
|
Experimentální: aETCC during TCog
Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog).
Duration: 20 minutes; Intensity: 2mA.
|
2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions.
In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
|
|
Experimentální: aETCC after TCog
Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog).
Duration: 20 minutes; Intensity: 2mA.
|
2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions.
In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
|
|
Falešný srovnávač: Simulated aETCC during TCog
Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog).
Duration: 20 minutes; Intensity: 2mA.
|
2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions.
In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in global cognitive function by the Alzheimer's Disease Assessment Scale (ADAS-Cog)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
Cognitive Scale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), consisting of 11 items that assesses performance related to memory, language, praxis and comprehension skills, with a maximum score of 70 points.
Thus, the higher the score, the more compromised the individual is.
Application takes about 30 minutes (Mohs & Cohen, 1988).
In addition, the Montreal Cognitive Assessment (MoCA), a cognitive screening tool created by Nasreddine et al. (2005).
|
baseline, after 4 weeks and after 12 weeks
|
|
Change in global cognitive function by the Montreal Cognitive Assessment (MoCA)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
MoCA is composed of eight cognitive domains, which are scored within a range of 0 to 30 points (higher scores indicate better function): short-term memory; visuospatial skills; executive function; verbal fluency; attention, concentration and working memory; language; sentence repetition; and spatiotemporal orientation.
|
baseline, after 4 weeks and after 12 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Executive Function by the Trail Making Test (TMT)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
The Trail Making Test (TMT) will be administered (Reitan, 1958).
From a clinical point of view, TMT is widely used as an indicator of brain dysfunction.
TMT is divided into two parts, TMT-A and TMT-B.
In the first, circles numbered 1 to 25 following the randomly arranged numerical sequence should be connected, time taken and considered, ie the task should be performed as soon as possible.
In the TMT-B task, the connection must alternate between numbers and letters.
The TMT (AB) scores consist of the time taken to complete each part, other derived scores are used, such as the difference score (TMT-B - TMT-A) and the ratio score (TMT-A) / TMT- B) (Llinàs-Reglà et al, 2015).
|
baseline, after 4 weeks and after 12 weeks
|
|
Change in Executive Function by the Tower of London
Časové okno: baseline, after 4 weeks and after 12 weeks
|
The Tower of London (Shallice, 1982) has been used in studies to evaluate executive function in elderly with AD (Satler, Guimarães, Tomaz, 2016).
Tower of London is made up of three vertical pins of different heights and three colored spheres, with a hole in the center to fit the pins.
The goal is to move them to reproduce, in a given number of moves, the position of a presented target figure.
There are 15 problems with increasing difficulty and reduced possibilities for moving parts.
Three attempts to resolve the issue are allowed.
Will be evaluated: total and average execution time, and total score, obtained by the sum of the points of each step, ranging from 0 to 3.
|
baseline, after 4 weeks and after 12 weeks
|
|
Change in Functionality by the Disability Assessment for Dementia (DAD)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
Disability Assessment for Dementia (DAD) (Gauthier, et al., 1997; Gélinas et al., 1999).
The DAD comprises 17 items that assess ADLs and 23 items that assess instrumental ADL (iADL) and leisure activities.
In the category related to ADLs are evaluated hygiene, dressing, undressing, continence and food.
IADL assessment and leisure activities consist of tasks related to meal preparation, phoning, sightseeing, finances and correspondence, medication and leisure, and housework (Feldman et al. (2001; Suh et al., 2004).
maximum score is 100, lower scores indicate higher level of impairment (Bahia et al., 2010).
|
baseline, after 4 weeks and after 12 weeks
|
|
Change in Neuropsychiatric symptoms by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
This outcome will be assessed with the Neuropsychiatric Inventory Questionnaire (NPI-Q; Kaufer et al., 2000).
This instrument consists of a self-administered caregiver scale and provides information on 12 characteristic behavioral and psychological symptoms in patients with dementia.
The severity level will be identified (1 = mild, 2 = moderate, 3 = severe).
The overall severity score ranges from 0 to 36, with zero indicating no neuropsychiatric symptoms.
The reliability and validity of this modified NPI score have been previously established (NPI-Q; Kaufer et al., 2000).
|
baseline, after 4 weeks and after 12 weeks
|
|
Change in Occupational performance by theCanadian Occupational Performance Measure (COPM)
Časové okno: baseline, after 4 weeks and after 12 weeks
|
The Canadian Occupational Performance Measure (COPM) (Law et al., 2009) will be used to assess occupational performance, ie engagement in daily activities.
The COPM is can be applied with the patient or caregiver, following four steps, firstly it seeks to identify which areas of occupational performance are impaired, ie, which occupations are compromised, and then assign a value from 1 to 10 to measure the degree of importance that the activities listed have for the interviewee or caregiver.
Next, five of these activities are organized by priority, and each of them should be assigned a value between 1 and 10 to describe the interviewee's performance and satisfaction respectively.
In the end, the averages of performance and satisfaction are calculated.
|
baseline, after 4 weeks and after 12 weeks
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Suellen Andrade, Universidade Federal da Paraíba
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
25. listopadu 2019
Primární dokončení (Očekávaný)
1. října 2020
Dokončení studie (Očekávaný)
1. prosince 2020
Termíny zápisu do studia
První předloženo
26. listopadu 2019
První předloženo, které splnilo kritéria kontroly kvality
6. ledna 2020
První zveřejněno (Aktuální)
7. ledna 2020
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
7. ledna 2020
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
6. ledna 2020
Naposledy ověřeno
1. ledna 2020
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CogAD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .